Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Enteric fever, caused by <i>Salmonella enterica</i> serovar Typhi (<i>S</i> Typhi) and <i>S. enterica</i> serovar Paratyphi (<i>S</i> Paratyphi), is a common travel-related illness. Limited data are available on the antimicrobial resistance (AMR) patterns of these serovars among travelers. Records of travelers with a culture-confirmed diagnosis seen during or after travel from January 2007 to December 2018 were obtained from GeoSentinel. Traveler demographics and antimicrobial susceptibility data were analyzed. Isolates were classified as nonsusceptible if intermediate or resistant or as susceptible in accordance with the participating site's national guidelines. A total of 889 travelers (<i>S</i> Typhi infections, <i>n</i> = 474; <i>S</i> Paratyphi infections, <i>n</i> = 414; coinfection, <i>n</i> = 1) were included; 114 (13%) were children of <18 years old. Most individuals (41%) traveled to visit friends and relatives (VFRs) and acquired the infection in South Asia (71%). Child travelers with <i>S</i> Typhi infection were most frequently VFRs (77%). The median trip duration was 31 days (interquartile range, 18 to 61 days), and 448 of 691 travelers (65%) had no pretravel consultation. Of 143 <i>S</i> Typhi and 75 <i>S</i> Paratyphi isolates for which there were susceptibility data, nonsusceptibility to antibiotics varied (fluoroquinolones, 65% and 56%, respectively; co-trimoxazole, 13% and 0%; macrolides, 8% and 16%). Two <i>S</i> Typhi isolates (1.5%) from India were nonsusceptible to third-generation cephalosporins. <i>S</i> Typhi fluoroquinolone nonsusceptibility was highest when infection was acquired in South Asia (70 of 90 isolates; 78%) and sub-Saharan Africa (6 of 10 isolates; 60%). Enteric fever is an important travel-associated illness complicated by AMR. Our data contribute to a better understanding of region-specific AMR, helping to inform empirical treatment options. Prevention measures need to focus on high-risk travelers including VFRs and children.

Original publication

DOI

10.1128/aac.01084-20

Type

Journal article

Journal

Antimicrobial agents and chemotherapy

Publication Date

20/10/2020

Volume

64

Addresses

Steven and Alexandra Cohen Children's Medical Center, North Shore-LIJ Health System, Division of Pediatric Infectious Diseases, New Hyde Park, New York, USA shagmann@northwell.edu.